Study S000469

A Clinical Study to Evaluate the Effect of MK-0616 and Semaglutide on Their Respective Pharmacokinetics in Healthy Adult Participants

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06699329
Study type: INTERVENTIONAL
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 38
Start: 2024-01-22
Primary completion: 2024-05-24
Lead sponsor: Merck Sharp & Dohme LLC
Conditions: Healthy
Interventions: DRUG:Enlicitide Decanoate; DRUG:Semaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:MK-0616-023

Registered primary outcomes

Area Under the Concentration-Time Curve from Time 0 to 24 hours (AUC0-24hrs) of Enlicitide Decanoate [At designated timepoints (up to 24 hours postdose)]
Area Under the Concentration-Time Curve from Time 0 to 24 hours (AUC0-24hrs) of Semaglutide [At designated timepoints (up to 24 hours postdose)]
Maximum Plasma Concentration (Cmax) of Enlicitide Decanoate [At designated timepoints (up to approximately 2 weeks postdose)]
Maximum Plasma Concentration (Cmax) of Semaglutide [At designated timepoints (up to approximately 2 weeks postdose)]
Time to Maximum Plasma Concentration (Tmax) of Enlicitide Decanoate [At designated timepoints (up to approximately 2 weeks postdose)]
Time to Maximum Plasma Concentration (Tmax) of Semaglutide [At designated timepoints (up to approximately 2 weeks postdose)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.